To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.

This bill, HR7902, aims to withdraw the FDA approval for mifepristone and establish a federal tort for harm caused by chemical abortion drugs. This action directly removes a pharmaceutical product from the market, impacting companies involved in its production, distribution, and related healthcare services. The bill's referral to the Energy and Commerce Committee, which oversees health policy, indicates it is moving through the relevant legislative channels. The sponsor, Rep. Harshbarger, is a Republican from Tennessee, indicating a partisan effort. There is no direct funding mechanism or appropriation in this bill. Instead, it creates a market contraction for specific pharmaceutical products and expands potential liability. Companies like Danco Laboratories, the primary manufacturer of mifepristone, would face a complete loss of this product line. Distributors such as McKesson ($MCK), Cardinal Health ($CAH), and AmerisourceBergen ($ABC) would see a reduction in their pharmaceutical distribution volume. Healthcare providers, including hospitals and clinics, would need to adjust their service offerings, potentially increasing demand for surgical abortion procedures or other reproductive health services. This could indirectly benefit companies providing surgical equipment or related services, though the overall impact on the broader healthcare sector is negative due to reduced access to a widely used medication. Historically, legislative actions directly impacting drug availability have had significant market effects. For example, when the FDA issued a black box warning for Avandia (rosiglitazone) in 2007, GlaxoSmithKline ($GSK) shares fell over 10% in the following weeks due to concerns about sales and liability. While not a complete ban, it demonstrates how regulatory or legislative restrictions on drug access directly impact pharmaceutical company valuations. More recently, state-level restrictions on abortion access following the Dobbs decision have led to shifts in healthcare service demand, with some clinics closing and others seeing increased patient volume for alternative services. This bill, if passed, would create a federal-level restriction, amplifying these effects. Specific losers include Danco Laboratories (private), which manufactures mifepristone. Publicly traded pharmaceutical companies like Pfizer ($PFE), Johnson & Johnson ($JNJ), and Merck ($MRK), while not directly manufacturing mifepristone, operate in a regulatory environment where such legislative actions set a precedent for federal intervention in drug approvals. This creates regulatory uncertainty for all pharmaceutical companies. Healthcare providers like DaVita ($DVA) and AMN Healthcare ($AMN) could see shifts in patient care needs, but the direct impact is less pronounced than on pharmaceutical manufacturers and distributors. CVS Health ($CVS) and Walgreens Boots Alliance ($WBA) would cease dispensing mifepristone, impacting their pharmacy revenues. The bill has been referred to committee. The next steps involve committee hearings and potential markups. If it passes committee, it would then move to a floor vote in the House. Given the current political climate, passage through both chambers and presidential approval is highly uncertain, but the introduction itself signals a legislative intent that creates market risk for companies involved in reproductive health pharmaceuticals. The timeline for committee action is undefined but could span several months to a year.